A TLR2 Agonist in German Cockroach Frass Activates MMP-9 Release and Is Protective against Allergic Inflammation in Mice

Kristen Page, John R. Ledford, Ping Zhou and Marsha Wills-Karp

*J Immunol* 2009; 183:3400-3408; Prepublished online 10 August 2009;
doi: 10.4049/jimmunol.0900838
http://www.jimmunol.org/content/183/5/3400

References

This article cites 53 articles, 19 of which you can access for free at:
http://www.jimmunol.org/content/183/5/3400.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
A TLR2 Agonist in German Cockroach Frass Activates MMP-9 Release and Is Protective against Allergic Inflammation in Mice

Kristen Page, John R. Ledford, Ping Zhou, and Marsha Wills-Karp

The role of TLR2 in modulating experimentally induced asthma is not fully understood. We recently identified that German cockroach (GC) frass contains a TLR2 ligand allowing us to investigate the role of a TLR2 agonist in a complex real world allergen in mediating allergic airway inflammation. GC frass exposure significantly increased airway inflammation, airway hyperresponsiveness and serum IgE levels in wild-type mice; however the same exposure in TLR2-deficient mice resulted in greatly exaggerated serum IgE and eosinophilia but diminished airway neutrophilia, suggesting a protective role for TLR2. Since GC frass inhalation usually induces airway neutrophilia, we queried the effect of neutrophil depletion on airway responses. Inhibition of neutrophil recruitment into the airways of naive wild-type mice before intratracheal inhalation of GC frass resulted in significantly increased levels of serum IgE and eosinophilia. Neutrophils are a rich source of MMP-9, and we found that MMP-9 levels were significantly increased in the airways of mice following exposure to GC frass. Importantly the levels of MMP-9 were significantly decreased in neutrophil-depleted and TLR2-deficient mice after exposure to GC frass, suggesting that TLR2 regulated MMP-9 release from neutrophils. Functionally, MMP-9-deficient mice had more acute allergic inflammation than wild-type mice, suggesting that MMP-9 was protective against experimentally induced asthma. These data suggest that TLR2 activation of neutrophils leads to release of MMP-9 which decreases allergic responses to GC frass. This suggests a protective role for TLR2 activation and MMP-9 release in the context of experimentally induced asthma in mice.

Asthma is a chronic inflammatory condition of the airways, characterized by airways hyperresponsiveness (AHR), persistent inflammation of the airways, increased serum IgE, excessive production of mucus, and airway remodeling. Asthma is also associated with the propensity for allergic Th type 2 (Th2) cell cytokine responses. Although there is a genetic predisposition for asthma, this cannot account for the significant increase in asthma prevalence over the past 20 years. Environmental factors, including house dust mite, cockroach, and cat exposure are thought to play a significant role in the increase in asthma (1). German cockroaches (GC; *Blattella germanica*) are the species that commonly infest homes in the United States. Cockroach allergens are important sensitizing agents, particularly in individuals who live in substandard, multifamily dwellings located in highly populated areas (2). Early life exposure to cockroach allergen was shown to predict allergen-specific responses by 2 years of age (3). Feces (frass) from cockroaches was purported to be the sensitizing agent (4), and in fact our laboratory has recently confirmed that GC frass can induce allergic inflammation in mice (5). Together these studies highlight the importance of cockroach in asthma pathogenesis and substantiate the use of GC frass in the current study.

Activation of the innate immune response is necessary for the induction of adaptive immunity. The innate immune system has evolved to recognize pathogen-associated molecular patterns (PAMPs), which are common to many classes of pathogens. PAMPs are recognized by pathogen recognition receptors, which include TLRs. TLRs have been shown to play a role in both the early phase of Ag recognition as well as in adaptive immunity (6). We have recently shown that GC frass contains a TLR2 ligand (7); however, the role of TLR2 in modulating the asthma phenotype is controversial. Previous studies have suggested that TLR2 may play a role in the initiation of asthma as selective TLR2 ligands administered during sensitization with OVA-enhanced Th2-mediated allergic inflammation (8, 9). However, other studies found that administration of TLR2 ligands inhibit OVA-induced Th2-mediated allergic responses (10) and inhibit OVA-induced established allergic airway inflammation by increasing the Th1 response (11). A recent report showed that addition of exogenous TLR2 ligands inhibited Th2 cytokine secretion from house dust mite-stimulated human PBMC from atopic individuals (12). The same study also showed increase of the co-stimulatory marker MHCII on myeloid dendritic cells following treatment with a TLR2 ligand. Collectively, these studies suggested that TLR2 plays a protective role in allergic asthma. Some of these discrepancies may be explained by the timing of the addition of the TLR2 ligand in the context of sensitization. To date, no one has ever investigated the effect of a TLR2 agonist inherent in a complex allergen.

Neutrophils play a crucial role in the innate host response. Our recent studies showed that the TLR2 agonist in GC frass activated neutrophil cytokine production (7). Other studies have found...
similar activation of neutrophils by selective TLR2 agonists. Treatment of bone marrow–derived neutrophils with PamCys, a selective TLR2 agonist, significantly increased cytokine expression in a NF-κB–dependent manner (13). Blocking TLR2 before treatment of human neutrophils with Helicobacter pylori resulted in decreased levels of cytokine expression (14). These data suggest that the early inflammatory response may be mediated by TLR2 activation on neutrophils. Numerous studies have identified a population of non-cosinophilic asthmatics, which appears to be associated with increased airway neutrophilia (reviewed in Ref. 15). Neutrophilic asthma has been associated with increased innate immune responses and increased TLR2 expression (16). Although still unclear, neutrophilic inflammation may play an important role in mediating the asthma phenotype, possibly by altering the innate immune response to allergens through the engagement and activation of TLR2.

Neutrophils are the richest source of MMP-9 in the body (~3 μg per million neutrophils) (17). MMP-9 belongs to a family of proteases that function in the degradation of several extracellular matrix components, and may play a role in airway remodeling. Levels of MMP-9 are significantly increased in the bronchoalveolar lavage (BAL) fluid, blood, and sputum of asthmatics (18–21). MMP-9 has been shown to be released from neutrophils following stimulation with the proinflammatory cytokine IL-8 (22). MMP-9 can be inhibited by endogenous inhibitor inhibitor of metalloproteinase (TIMP)-1; however, neutrophils uniquely release TIMP-free MMP-9 (23). The overall role of MMP-9 in asthma pathogenesis has been investigated using the OVA model of allergic airway inflammation. One group found that MMP-9-deficient mice had impaired cellular infiltration, Th2 cytokine expression and AHR following OVA treatment (24), while another group showed that MMP-9 deficiency resulted in enhanced allergic inflammation in mice also following OVA treatment (25). The differences between these findings were suggested to be due to the level of airway inflammation, and eosinophilia between the two experiments, wild-type (BALB/c or FVB) or MMP-9-deficient mice were administered an intratracheal (i.t.) inhalation as previously described (28). Mice were imaged and ventilated at a rate of 120 breaths per minute with a constant tidal volume of air (0.2 ml), and paralyzed with decamethonium bromide (25 mg/kg). After establishment of a stable airway pressure, 25 μg/kg weight of acetylcholine was injected i.v. and dynamic airway pressure (airway pressure time index (APTI) in cm H2O × s−1) was followed for 5 min.

Cytokine production

Liberase/DNase I digests of the lung were prepared to obtain single lung cell suspensions. Single cell suspensions (2.5 × 106) were incubated for 72 h in culture medium (RPMI 1640) treated with concanavalin A (10 μg/ml) and supernatants were analyzed for IL-5 and IL-13 levels by ELISA (R&D Systems) (28).

Assessment of airway inflammation

Lungs were lavaged thoroughly with 1 ml of HBSS without calcium or magnesium. The lavage fluid was centrifuged (1800 rpm for 10 min), the supernatant was removed for cytokine analysis and immediately stored at −80°C. Total cell numbers were counted on a hemocytometer. Smears of BAL cells prepared with a Cytospin II (Shandon) were stained with Diff-Quick solution for differential cell counting. BAL fluid was analyzed by ELISA according to the manufacturer’s specifications (R&D Systems).

Serum IgE and IgG1 levels

Serum was obtained from blood taken during exsanguination of the animals after airway measurements. ELISAs for IgE and IgG1 were performed as previously described (31). For frass-specific IgE, ELISA plates were coated with 50 μm of GC frass (100 μm/ml) in HBSS overnight at room temperature. The remainder of the ELISA is performed as previously described (31). Plates were read at 405 nm.

Lung histology

Whole lungs were removed and formalin fixed. Lungs were embedded in paraffin, sectioned, and stained with periodic acid Schiff (PAS).

MMP-9 analysis

BAL fluid was subject to gelatin zymography on an 8% SDS-PAGE containing 1 mg/ml gelatin under non-reducing conditions as described previously (26). Mature (active) MMP-9 was determined by Western blot under reducing conditions (R&D Systems).

Cell culture

HL-60 promyelocytic leukemia cells (American Type Culture Collection) were cultured in RPMI 1640 medium supplemented with 10% FBS 50 μg/ml streptomycin, 2 U/ml penicillin, and 2 mM l-glutamine. For differentiation, cells (1 × 106/ml) were incubated in the presence of 1% DMSO for 3 days. Cells were centrifuged, washed, and deprived of serum for 6 h. Cells were treated with GC frass (100 ng/ml) or the TLR2-selective agonist PamCys-Ser-Lys (30 μM; EMD Biosciences) before treatment with GC frass. Supernatants were clarified and analyzed for MMP-9 by ELISA (R&D Systems).

Mouse bone marrow–derived neutrophils

Femurs and tibias were removed from C57BL/6 or TLR2-deficient mice. Bone marrow was isolated and rinsed and RBCs were lysed. Resuspended cells were layered onto a three-step Percoll gradient (52%, 64%, 72%) and centrifuged (1000 rpm for 30 min at RT). The bottom layer (64%–72%) containing neutrophils was collected, counted, and plated. Cells were

The Journal of Immunology
treated with GC frass (300 ng/ml) or TNF-α (10 ng/ml; R&D Systems) for 18 h, and supernatants were analyzed by ELISA.

Isolation of primary human neutrophils
Following approval by the Institutional Review Board and with informed consent, blood was collected using sterile technique from healthy volunteers for isolation of polymorphonuclear leukocytes. Blood was collected and BAL fluid was harvested. In all cases, means ± SEM (n = 6–8 mice per group) were reported. Statistical significance was determined by ANOVA. A, AHR was measured as airway pressure time index (APTI) in cm-H₂O x sec −1 (compared with PBS *, p = 0.019, **, p = 0.003). B, IL-5 levels (compared with PBS *, p = 0.001, **, p = 0.004). C, IL-13 levels (compared with PBS *, p = 0.004, **, p = 0.013). D, Serum IgE levels (compared with PBS *, p < 0.01; compared with GC frass **, p < 0.001). E, Frass-specific IgE levels (compared with PBS *, p < 0.001; compared with GC frass **, p = 0.019). F, Serum IgG1 levels (compared with PBS *, p0.025, **, p < 0.001; compared with GC frass ***, p = 0.007).

Results
TLR2-deficient mice had increased serum IgE and eosinophilia in experimentally induced asthma
Since GC frass contains a TLR2 ligand (7), we queried the involvement of TLR2 activation in regulating experimentally induced asthma in our mouse model. We sensitized wild-type and TLR2-deficient mice via intraperitoneal injection of GC frass bound to alum and challenged with intratracheal inhalation of GC frass. In line with our previous report (5), sensitization and challenge of GC frass significantly increased the following parameters: airway responsiveness to cholinergic agents (Fig. 1A), Th2 cytokine expression IL-5 and IL-13 (Fig. 1B and C), serum IgE levels (Fig. 1D), GC frass-specific IgE levels (Fig. 1E), serum IgG1 levels (Fig. 1F), and cellular infiltration into the BAL fluid (Table I).

Table 1. Differential cell count in BAL fluid of sensitized and challenged wild-type (C57BL/6) and TLR2-deficient (TLR2−/−) mice

<table>
<thead>
<tr>
<th></th>
<th>Mac</th>
<th>Epi</th>
<th>Eos</th>
<th>Neut</th>
<th>Lymph</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57-PBS</td>
<td>3.4 ± 1.1</td>
<td>3.7 ± 1.4</td>
<td>0.03 ± 0.02</td>
<td>0.03 ± 0.02</td>
<td>0.02 ± 0.006</td>
</tr>
<tr>
<td>TLR2−/− PBS</td>
<td>10.1 ± 2.7</td>
<td>6.1 ± 1.7</td>
<td>0.014 ± 0.008</td>
<td>0.073 ± 0.03</td>
<td>0.07 ± 0.06</td>
</tr>
<tr>
<td>C57-frass</td>
<td>95.6 ± 22.7</td>
<td>20.5 ± 6.4</td>
<td>21.4 ± 8.1</td>
<td>55.1 ± 17.3</td>
<td>37.25 ± 10.2</td>
</tr>
<tr>
<td>TLR2−/− frass</td>
<td>26.8 ± 2.5*</td>
<td>3.3 ± 0.3**</td>
<td>55.8 ± 12.3**</td>
<td>3.8 ± 1.0*</td>
<td>5.2 ± 0.7*</td>
</tr>
</tbody>
</table>

* C57BL/6 mice were given i.p. injections of PBS or GC frass with alum on days 0 and 7. Intratracheal inhalations of PBS or GC frass were performed on days 14 and 19. On day 22, BALF was harvested and differential cell counts performed. These data represent 6–8 mice per group and are expressed as mean ± SEM of cell number × 10⁷. Cell counts were statistically significant between GC frass in the TLR2-deficient mice compared with wild-type mice (*, p < 0.001; **, p = 0.003), as determined by ANOVA.
Importantly, TLR2 deficiency altered some aspects of experimentally induced asthma. For example, airway responsiveness (Fig. 1A) and levels of Th2 cytokines (Fig. 1, B and C) were not significantly altered in TLR2-deficient mice; while levels of serum IgE (Fig. 1D), GC frass-specific IgE (Fig. 1E), serum IgG1 (Fig. 1F), and infiltration of eosinophils (Table I) were significantly increased. Infiltration of tissues with neutrophils, lymphocytes, and macrophages were significantly decreased in the TLR2-deficient mice (Table I). These results suggest that TLR2 plays a role in some aspects of allergen-induced allergic inflammation.

The role of neutrophils in regulating experimentally induced asthma

We have recently shown that inhalation of GC frass induces neutrophilia. Since inhalation of GC frass normally induces airway neutrophilia (7), and we detect a decrease in neutrophilia in the TLR2-deficient mice, we queried the role of early neutrophil infiltration on mediating allergic inflammation. To do this, we used a protocol we have previously shown to abolish neutrophil infiltration following GC frass inhalation (7). RB6-8C5, an Ab that depletes circulating neutrophils (29) was administered by intraperitoneal injection 24 h before each intratracheal challenge with GC frass. We have previously shown this to completely abolish GC frass-induced neutrophil recruitment into the airways (7). In this experiment, we used BALB/c mice, which we have shown exhibit airway inflammation and hyperresponsiveness to GC frass by inhalation only (5). Mice were given an injection of the isotype control Ab or RB6–8C5 (100 μg/mouse) 24 h before a single intratracheal inhalation of PBS (40 μl) or GC frass (40 μg/40 μl) on days 0, 7, and 14. On day 17, BALF was harvested and differential cell counts performed. These data represent 4 mice per group and are expressed as mean ± SEM of cell number × 10⁶. Statistical significance between isotype control Ab-treated mice and RB6-8C5 Ab-treated mice are shown (*, p = 0.005; **, p = 0.015; as determined by ANOVA).

<table>
<thead>
<tr>
<th>Group</th>
<th>Mac</th>
<th>Epi</th>
<th>Eos</th>
<th>Neut</th>
<th>Lymph</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>5.8 ± 0.8</td>
<td>3.1 ± 1.2</td>
<td>0</td>
<td>0</td>
<td>0.23 ± 0.18</td>
</tr>
<tr>
<td>GC frass</td>
<td>21.9 ± 3.8</td>
<td>1.5 ± 0.7</td>
<td>1.5 ± 0.06</td>
<td>4.9 ± 0.6</td>
<td>5.9 ± 0.8</td>
</tr>
<tr>
<td>RB6-8C5 Ab</td>
<td>21.9 ± 3.2</td>
<td>2.2 ± 0.6</td>
<td>7.2 ± 1.9**</td>
<td>1.3 ± 0.3**</td>
<td>7.7 ± 1.8</td>
</tr>
</tbody>
</table>

*BALB/c mice were given an i.p. injection of control Ab or RB6-8C5 Ab on days 1, 6, and 13, while an intratracheal inhalation was performed with PBS or GC frass (40 μg/40 μl) on days 0, 7, and 14. On day 17, BALF was harvested and differential cell counts performed. These data represent 4 mice per group and are expressed as mean ± SEM of cell number × 10⁶. Statistical significance between isotype control Ab-treated mice and RB6-8C5 Ab-treated mice are shown (*, p = 0.005; **, p = 0.015; as determined by ANOVA).

**FIGURE 2.** Neutrophil recruitment directly affected MMP-9 release into the airways. BALB/c mice were given a single injection of control Ab or RB6–8C5 (100 μg/mouse) 24 h before a single intratracheal inhalation of PBS (40 μl) or GC frass (40 μg/40 μl). 3 h later, mice were given a lethal dose of sodium pentobarbital and BAL fluid was harvested. Neutrophils were quantified following differential staining and a MMP-9 ELISA was performed on the BAL fluid. In all cases, means ± SEM (n = 6 mice per group) were reported. Statistical significance was determined by ANOVA. A, Neutrophil influx into BAL fluid (*, p < 0.001) (nd = none detected). B, MMP-9 ELISA of BAL fluid (*, p < 0.001).

**GC frass-induced neutrophil influx is responsible for increased MMP-9 expression**

Neutrophils are a rich source of MMP-9, so we queried whether MMP-9 levels were affected by neutrophil depletion. To test this, we first pretreated mice with the RB6-8C5 Ab for 24 h before a single intratracheal inhalation of GC frass. Not surprisingly, GC frass inhalation significantly increased neutrophil numbers in the airways of mice 3 h post inhalation. Pretreatment with RB6-8C5 totally abolished GC frass-induced neutrophil accumulation in the airways (Fig. 2A). Concurrent with the decrease in neutrophils, the concentration of MMP-9 in the BAL fluid was significantly decreased to below baseline levels (Fig. 2B). These data suggest that newly recruited airway neutrophils release significant concentrations of MMP-9 in the BAL fluid of mice following an intratracheal inhalation.

**MMP-9 levels in BAL fluid**

Next, we examined MMP-9 expression in the BAL fluid 3 and 18 h following a single intratracheal inhalation of PBS or GC frass in naive BALB/c mice. Three hours postinhalation, MMP-9 and its natural inhibitor TIMP-1 were significantly up-regulated in the GC frass-treated mice as determined by ELISA (Table III). By 18 h postinhalation of GC frass, MMP-9 levels were lower (25 ± 1.5 ng/ml, n = 7 mice compared with undetectable levels in PBS-treated mice) but were still significantly increased compared with PBS-treated mice. While MMP-9 levels were higher at 3 h, the...
next set of experiments was run at 18 h because active proteases in GC frass also showed up on the gelatin zymogram and made analysis difficult. Gelatin zymography of BAL samples revealed MMP-9 digestion of the gelatin impregnated gel compared with PBS-treated mice (Fig. 3A). In addition, active MMP-9 was detected in only the GC frass-treated BAL samples and not BAL from PBS-treated mice (Fig. 3B). These data show that MMP-9 was significantly increased in the airways of mice following GC frass exposure.

**TLR2 partially mediates MMP-9 expression in mouse airways**

To test the role of TLR2 in GC frass-induced release of MMP-9 into the BAL fluid, we administered GC frass with a single intratracheal inhalation in wild-type and TLR2−/− mice. Neutrophil infiltration into the airways was slightly but not significantly decreased following GC frass treatment in TLR2-deficient mice 3 h following GC frass inhalation (Fig. 4A). GC frass inhalation induced a significant increase in MMP-9 and MMP-9:TIMP levels, which was significantly attenuated in the TLR2−/− mice (Fig. 4, B and C). A similar decrease in MMP-9 levels is also seen 18 h following GC frass inhalation in TLR2−/− mice compared with wild-type controls (data not shown). These data suggest that although TLR2 is not required for neutrophil recruitment into the airways, it is necessary for neutrophil-derived MMP-9 release. Therefore, we asked whether MMP-9 levels were altered in the TLR2-deficient mice sensitized and challenged with GC frass (refer to Fig. 1). We found that sensitization to GC frass induced significant levels of MMP-9 (frass exposed 1084.3 ± 386.4 pg/ml compared with PBS 80.3 ± 75.1 pg/ml, *, p = 0.01, n = 6–8 mice per group) in wild-type mice. TLR2-deficient mice sensitized to GC frass had significantly lower amounts of MMP-9 in their BAL fluid (frass exposed 345.8 ± 163.2 pg/ml compared with PBS 54.6 ± 31 pg/ml, *, p = 0.02, n = 6–8 mice per group). Together, these data suggest that TLR2 activation resulted in the release of MMP-9 into the BAL fluid of mice.

**TLR2 activation directly affects MMP-9 expression/release from neutrophils**

We have recently shown that neutrophils express TLR2 on their surface by flow cytometry (7). To show that GC frass induced the release of MMP-9 from neutrophils, we isolated primary human neutrophils from four normal donors and treated them ex vivo with GC frass for 4 h. We found that GC frass treatment resulted in the release of MMP-9 (42.3 ± 6.8 ng/ml compared with control 12.7 ± 2.5 ng/ml; n = 4, *, p = 0.007). We confirmed these data using DMSO-differentiated human HL-60 cells. Treatment of HL-60 cells with GC frass or the selective TLR2 agonist Pam3Cys both resulted in a significant release of MMP-9 into the media (Fig. 5A). Of note, removal of the TLR2 agonist from GC frass using lipoprotein lipase resulted in attenuated GC frass-induced MMP-9 expression (Fig. 5A), but had no effect on Pam3Cys-induced MMP-9 expression. Since we have previously shown that GC frass induced NF-κB translocation and activation in human neutrophils, we asked whether GC frass-induced regulation of MMP-9 expression was dependent on activation of NF-κB. To do this, we pretreated HL-60 cells with the NF-κB inhibitor isohelenin, before the

**FIGURE 3.** MMP-9 levels were increased in BAL fluid of GC frass-treated mice. BALB/c mice were given a single intratracheal inhalation of PBS or GC frass and BAL fluid was harvested 18 h later. MMP-9 activity was measured in the BAL fluid as determined by gelatin zymogram (A) or Western blot analysis using an Ab against the mature (active) form of MMP-9 (B).

**FIGURE 4.** Neutrophil accumulation and MMP-9 levels in the airways of TLR2-deficient mice. Wild-type (C57BL/6) and TLR2-deficient mice were given a single intratracheal inhalation of PBS (40 µl) or GC frass (40 µg/40 µl), and 3 h later, BAL fluid was harvested and neutrophils were quantified following differential staining or ELISA was performed. In all cases, means ± SEM (n = 6 mice per group) were reported. Statistical significance was determined by ANOVA. A, Neutrophil influx into BAL fluid (compared with PBS *, p = 0.002, **, p = 0.017; ns = not significant). B, MMP-9 ELISA of BAL fluid (*, p < 0.001). C, Ratio of MMP-9 to TIMP-1 (*, p < 0.001).
addition of GC frass. Inhibition of NF-κB activation abolished GC frass-induced MMP-9 expression, suggesting the mechanism by which GC frass increased MMP-9 (Fig. 5B). To directly address a difference in the amount of MMP-9 released from wild-type and TLR2-deficient neutrophils, bone marrow-derived neutrophils were isolated and treated in the absence or presence of GC frass. GC frass treatment resulted in increased levels of MMP-9 in wild-type, but not in TLR2-deficient bone marrow-derived neutrophils (Fig. 5C). There was no defect in TLR2-deficient mice synthesizing or releasing MMP-9 as evidenced by the fact that control levels of MMP-9 and MMP-9 levels following TNF-α treatment were comparable between wild-type and TLR2-deficient mice. Together these data show that GC frass can directly regulate MMP-9 release from neutrophils and shows that the TLR2 ligand in GC frass is an important component for the release of MMP-9.

**Induced allergic inflammation is increased in MMP-9-deficient mice**

To determine a role for MMP-9 in airway inflammation and the development of airway dysfunction, we sensitized and challenged wild-type (FVB) or MMP-9-deficient mice by intratracheal inhalation with GC frass. Sensitization and challenge with GC frass significantly increased airway responsiveness to cholinergic agents in wild-type mice; however, this was significantly increased in MMP-9-deficient mice (Fig. 6A). Levels of the Th2 cytokines IL-5 and IL-13 were increased in wild-type mice following allergen challenge and were higher in MMP-9-deficient mice compared with wild-type mice treated with GC frass (Fig. 6, B and C). Serum IgE levels (Fig. 6D), GC frass-specific IgE (Fig. 6E), and serum IgG1 levels (Fig. 6F) were also increased following sensitization and challenge with GC frass and were higher in MMP-9-deficient mice. Interestingly, MMP-9-deficient mice sensitized to GC frass had significantly more eosinophils and less neutrophils than wild-type mice (Table IV), reminiscent of the TLR2-deficient phenotype.

Histological examination of the wild-type or MMP-9-deficient mouse lungs following GC frass treatment showed dense perivasculature and peribronchiolar infiltrates compared with PBS treatment (data not shown). There was not a significant difference between the levels of infiltrates in wild-type or MMP-9-deficient mice. Interestingly, we did not detect any PAS staining in the lungs of the wild-type FVB or MMP-9-deficient mice sensitized and challenged with PBS (Fig. 7, A and C). Sensitization and challenge with GC frass induced some mucin in the wild-type mice (Fig. 7B); however, there was significantly more PAS staining in the MMP-9-deficient mice (Fig. 7D). Therefore, concurrent with the increase in IL-13 and airway hyperresponsiveness, the levels of mucin in the epithelial cells in the MMP-9-deficient mice was significantly worse than in wild-type mouse lungs. Combined, these data suggest that MMP-9 plays a protective role in the asthma phenotype, because we have shown that MMP-9-deficient mice have a significantly increased allergic inflammatory response and airway reactivity.

**Discussion**

Herein we show that a real world allergen, among its other constituents, contains a TLR2 agonist that acts to protect against experimentally induced asthma in mice. Using a real world allergen containing a TLR2 ligand, we found that GC frass activated TLR2 on neutrophils to release MMP-9, and the increased levels of MMP-9 in the airways played a protective role in the generation of experimentally induced asthma in our murine model. To our knowledge, this is the first report showing that TLR2 regulated MMP-9 release from neutrophils. Activation of TLR2 mediated the release of MMP-9 from neutrophils as evidenced by 1) MMP-9 levels detected in the BAL fluid of mice following GC frass exposure was dependent on neutrophil infiltration into the airways, 2) selective activation of TLR2 increased MMP-9 release from neutrophils in culture, 3) removal of the TLR2 ligand in GC frass or treating TLR2-deficient neutrophils with GC frass attenuated MMP-9 release, and 4) TLR2-deficient mice released similar levels of MMP-9 following TNF-α treatment. In addition, we found that inhibition of NF-κB signaling attenuated GC frass-induced MMP-9 expression. This follows our previous data showing that GC frass induced NF-κB translocation and activation (7). Together
these data suggest that TLR2 activation leads to increased MMP-9 release from neutrophils. We next queried the physiological relevance of altered MMP-9 in the context of experimentally induced asthma. MMP-9-deficient mice that were sensitized and challenged with GC frass by intratracheal inhalation had significantly more allergic airway inflammation. In addition, our study links activation of TLR2 to the regulation of MMP-9 in the airways by showing in TLR2-deficient mice that TLR2 is upstream of MMP-9 regulated experimentally induced asthma are consistent with the MMP-9-deficient mice. TLR2 is upstream of a number of mediators, one of which is MMP-9, so the fact that not all parameters tested were altered in TLR2-deficient mice was not surprising. Overall our data suggests that the TLR2 ligand in GC frass activates neutrophils to release MMP-9, the consequence of which is to lessen airway inflammation and airway reactivity in a mouse model of experimentally induced asthma.

The effect of the innate immune response on activation of adaptive immunity and subsequent allergic inflammation is unclear. In every system tested to date, an immediate consequence of allergen inhalation in rodent and human models is the increase in airway neutrophilia (7, 33–35); however, the consequence of this is currently unknown. Our findings that inhibition of neutrophil

Table IV. Differential cell count in BAL fluid of sensitized and challenged wild-type (FVB) and MMP-9-deficient (MMP−/−) mice

<table>
<thead>
<tr>
<th></th>
<th>Mac</th>
<th>Epi</th>
<th>Eos</th>
<th>Neut</th>
<th>Lymph</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVB-PBS</td>
<td>1.1 ± 0.3</td>
<td>1.7 ± 0.4</td>
<td>0.01 ± 0.004</td>
<td>0.01 ± 0.005</td>
<td>0.009 ± 0.005</td>
</tr>
<tr>
<td>MMP-9−/− PBS</td>
<td>1.7 ± 0.4</td>
<td>1.9 ± 0.5</td>
<td>0.04 ± 0.03</td>
<td>0.02 ± 0.01</td>
<td>0.04 ± 0.02</td>
</tr>
<tr>
<td>FVB frass</td>
<td>13.7 ± 2.4</td>
<td>8.2 ± 2.2</td>
<td>53.9 ± 17</td>
<td>0.5 ± 0.1</td>
<td>3.3 ± 0.5</td>
</tr>
<tr>
<td>MMP-9−/− frass</td>
<td>15.3 ± 1.7</td>
<td>8.3 ± 2.7</td>
<td>139 ± 17</td>
<td>0.03 ± 0.02</td>
<td>3.5 ± 1</td>
</tr>
</tbody>
</table>

FVB or MMP-9-deficient mice were given intratracheal inhalations of PBS (40 μl) or GC frass (40 μg/40 μl) on days 0, 7, and 14. On day 17, BALF was harvested and differential cell counts performed. These data represent 6–8 mice per group and are expressed as mean ± SEM of cell number × 10⁶. Cell counts were statistically significant between GC frass in the MMP-9-deficient mice and wild-type mice (*, p = 0.002; **, p < 0.001, as determined by ANOVA).
infiltration following each inhalation of GC frass resulted in increased airway eosinophilia and serum IgE levels suggest that activation of neutrophils play some role in the mediating the allergic asthma phenotype. Intriguingly, it has been shown that transfer of Th1 cells, which induced airway neutrophilia, followed by challenge with OVA was unable to increase airway hyperresponsiveness in mice (36). Importantly, this study may support our hypothesis that it is not neutrophil infiltration per se that regulates airway hyperresponsiveness, but the interaction of the allergen GC frass with the neutrophil. Although we believe a direct interaction of GC frass and the newly recruited neutrophil occurs, other possibilities could exist. For example, newly recruited neutrophils may release a mediator that regulates MMP-9 release either from neutrophils or possibly from another cellular source in the airway. We have previously shown that GC frass can regulate MMP-9 release from bronchial epithelial cells (26); however, these levels were significantly lower than those from neutrophils. Alveolar macrophages are also capable of releasing MMP-9 (K. Page, unpublished observation); however, these levels are also not comparable to those released by the neutrophil. In addition, we have recently reported that GC frass increased NF-κB activation in neutrophils (7), and now present evidence that TLR2 regulates MMP-9 expression via activation of NF-κB. Overall, our data suggests that the interaction of GC frass with newly recruited neutrophils mediates the release of MMP-9 into the airways.

The fact that MMP-9 depletion increased airway inflammation and airway reactivity were a surprise to us, because we were anticipating that without the degradative effects of MMP-9, the allergic asthma phenotype would be lessened. MMP-9 is known to process and activate pro-IL-1β (37), IL-8 (38), and TNF-α (39), all of which are important in inflammation. The question is then, how does the removal of MMP-9 increase inflammation? One possibility is that there is compensation by another MMP in the absence of MMP-9, which perhaps is usually found in lower concentrations in the airways and is up-regulated in the MMP-9-deficient mice. We did not investigate the concentrations of the other MMPs in this study; however, Yoon et al. (40) found significant up-regulation of MMP-2 in the MMP-9-deficient mice. Another possibility is that depletion of MMP-9 results in the loss of activation or degradation of other proteins. For example, it has been shown that MMP-9 proteolytically activates TGFβ (41). TGFβ has been shown to inhibit IgE synthesis, mast cell proliferation, and eosinophil survival in a number of studies (42–44). Meade et al. (45) showed that TGFβ1 inhibited immediate and delayed hypersensitivity in a mouse model. It is conceivable then that MMP-9 deficiency may lead to the lack of TGFβ activation and thus an increase in the asthma phenotype. Further studies will investigate the role for TGFβ in GC frass-induced innate immune responses and experimentally induced asthma in our mouse model.

Our present study is in disagreement with another study that showed that MMP-9-deficient mice had decreased airway inflammation and decreased airway responsiveness to carbachol (24). The main differences in our studies are the mode of sensitization and the choice of allergen. Our model uses a real world allergen and a physiologically relevant mode of sensitization, namely inhalation. Recent data have shed light on the importance of the airway epithelium in asthma pathogenesis (46, 47). The use of OVA bound to aluminum hydroxide (alum) and administered via intraperitoneal injection results in highly enhanced T cell responses, but does not activate the airway epithelium as inhalation of an allergen would. The fact that the outcome of the two studies is different may shed light on the importance of the airway epithelial involvement in the pathogenesis of asthma.

Overall, our data suggest that activation of TLR2 plays a protective role in experimentally induced asthma in mice. Although GC frass contains the cockroach allergens Bla g1 and Bla g2 (4), it also contains active serine proteases (26, 48), coliform bacteria (49), LPS (50) (a TLR4 agonist) and a TLR2 agonist (7), phenomones, and a number of other uncharacterized components. It is likely that all of these components play important roles in mediating allergic inflammation. It is possible that the degree to which an individual responds to various components contained within the allergen complex may alter the asthma phenotype. Polymorphisms in TLR2 have been suggested to be associated with increased asthma susceptibility. A cross-sectional study performed to identify polymorphisms in TLR2 in children from rural areas in Austria and Germany (51), showed that a polymorphism in TLR2 (A-16934T) allele was found to be a major determinant of the susceptibility to asthma and allergies. A subsequent study found an association between TLR2+/S96 and asthma in a case-control and family-based analysis (52). However another study in Japanese children showed no such association (53). Nevertheless, our study using a complex allergen suggests that at least one component, the TLR2 agonist, plays a protective role in determining the susceptibility to asthma by mediating MMP-9 release by neutrophils.

Acknowledgments
We thank Dr. Shizuo Akira for providing the TLR2+/− mice.

Disclosures
The authors have no financial conflict of interest.

References
3408 TLR2 ACTIVATES MMP-9 AND PROTECTS AGAINST ASTHMA IN MICE


